AMGN - Amgen Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Business Description

Amgen Inc. Overview

Business Nature
Amgen Inc. is a leading global biotechnology company that focuses on discovering, developing, manufacturing, and marketing human therapeutics by leveraging advancements in molecular and cellular biology. The company primarily operates in therapeutic areas such as hematology, oncology, and inflammation. Through extensive research and development efforts, Amgen aims to provide innovative solutions that address significant medical needs.

Key Acquisitions and Strategic Position
In 2002, Amgen acquired Immunex Corporation for $18 billion, a move that significantly enhanced Amgens presence in the biotechnology sector. This acquisition not only diversified Amgen’s product offerings but also enriched its research capabilities in therapeutic proteins and antibodies.

Core Products
Amgens renowned products include:

- EPOGEN® (Epoetin alfa) and Aranesp® (darbepoetin alfa): Both of these products stimulate red blood cell production, addressing anemia linked to chronic renal failure and chemotherapy.

- Neulasta® (pegfilgrastim) and NEUPOGEN® (Filgrastim): These products support white blood cell production, helping reduce the risk of infection during cancer treatment.

- ENBREL® (etanercept): This medication inhibits tumor necrosis factor (TNF), serving as a treatment for autoimmune conditions such as rheumatoid arthritis and psoriatic arthritis.

Other notable products in Amgens portfolio include Kineret® (anakinra) and Stemgen® (Ancestim), which address various medical conditions.

Research and Development Focus
Amgens R&D efforts are centered on creating therapeutics in the forms of proteins, monoclonal antibodies, and small molecules across multiple fields including hematology, oncology, inflammation, metabolic and bone disorders, and neuroscience. The company operates with research facilities in the U.S. and clinical development teams deployed in various regions such as Europe, Canada, Australia, and Japan. Amgen maintains a robust pipeline of potential new therapies through both internal research and strategic collaborations.

Manufacturing and Operations
The company has commercial manufacturing facilities located in the United States, Puerto Rico, and a distribution center in the Netherlands. Additionally, Amgen collaborates with contract manufacturers, such as Boehringer Ingelheim Pharma KG, to supply some of its high-demand products.

Market Competition
Amgen faces competition across its therapeutic categories from other major pharmaceutical companies developing similar products. For instance:
- In the anemia treatment space, Aranesp® and EPOGEN® compete with products from Johnson & Johnson, Aventis Pharmaceuticals, and Roche, among others.
- For autoimmune disease therapies like ENBREL®, Amgen competes with various medications from companies including abbott, Merck, and Pfizer, as well as generics.

Conclusion
Amgen Inc. is a pivotal player in the biotechnology industry, strengthening its market position through strategic acquisitions, a diverse product line, and a firm commitment to research and innovation. The company prioritizes advancing human health through targeted therapies and addressing critical health challenges across multiple therapeutic areas.

Amgen and Kyowa Kirins Rocatinlimab Shows Promise in Phase 3 Study Amid Growth in Supplier Performance

Published Tue, Sep 9 2025 6:56 AM UTC

In a remarkable development within the biopharmaceutical sector, Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) have disclosed preliminary top-line results from the ASCEND Phase 3 long-term extension study. This study investigates the efficacy of rocatinlimab, an innovative investigational therapy that rebalances T-cells by targeting the OX40 receptor, specifically...

Advancements and Financial Dynamics in Oncological Immunotherapy An Insight into Asher Bio and Amgen Inc.

Published Wed, Jan 8 2025 5:55 PM UTC

The field of oncology has seen remarkable innovations in recent years, particularly in the realm of targeted immunotherapy. A significant development has emerged with Asher Biotherapeutics announcing a clinical trial collaboration and supply agreement with Amgen Inc. to investigate etakafusp alfa (formerly known as AB248). This investigational therapy, designed to target CD8...

Fundamental Analysis

Reportable Segment

100 %

of total Revenue

Product sales

95.36 %

of total Revenue

Product sales Reportable Segment

95.36 %

of total Revenue

Other revenues

4.64 %

of total Revenue

Other revenues Reportable Segment

4.64 %

of total Revenue

Repatha

10.16 %

of total Revenue

Repatha U S

5.4 %

of total Revenue

Repatha ROW

4.77 %

of total Revenue

Prolia

8.44 %

of total Revenue

Prolia U S

5.35 %

of total Revenue

Prolia ROW

3.09 %

of total Revenue

EVENITY

6.52 %

of total Revenue

EVENITY U S

5 %

of total Revenue

EVENITY ROW

1.52 %

of total Revenue

TEPEZZA

5.69 %

of total Revenue

TEPEZZA U S

4.92 %

of total Revenue

TEPEZZA ROW

0.77 %

of total Revenue

Otezla

5 %

of total Revenue

Otezla U S

4.08 %

of total Revenue

Otezla ROW

0.92 %

of total Revenue

BLINCYTO

4.82 %

of total Revenue

BLINCYTO U S

2.56 %

of total Revenue

BLINCYTO ROW

2.25 %

of total Revenue

Nplate

4.78 %

of total Revenue

Nplate U S

3.28 %

of total Revenue

Nplate ROW

1.5 %

of total Revenue

XGEVA

4.77 %

of total Revenue

XGEVA U S

2.65 %

of total Revenue

XGEVA ROW

2.12 %

of total Revenue

TEZSPIRE

3.98 %

of total Revenue

TEZSPIRE U S

3.98 %

of total Revenue

KYPROLIS

3.83 %

of total Revenue

KYPROLIS U S

2.53 %

of total Revenue

KYPROLIS ROW

1.3 %

of total Revenue

ENBREL

3.71 %

of total Revenue

ENBREL U S

3.64 %

of total Revenue

ENBREL ROW

0.07 %

of total Revenue

Aranesp

3.61 %

of total Revenue

Aranesp U S

0.89 %

of total Revenue

Aranesp ROW

2.72 %

of total Revenue

Vectibix

3.33 %

of total Revenue

Vectibix U S

1.58 %

of total Revenue

Vectibix ROW

1.75 %

of total Revenue

UPLIZNA

3.04 %

of total Revenue

UPLIZNA U S

2.85 %

of total Revenue

UPLIZNA ROW

0.19 %

of total Revenue

IMDELLTRA IMDYLLTRA

2.99 %

of total Revenue

IMDELLTRA IMDYLLTRA U S

2.18 %

of total Revenue

IMDELLTRA IMDYLLTRA ROW

0.81 %

of total Revenue

KRYSTEXXA

2.96 %

of total Revenue

KRYSTEXXA U S

2.96 %

of total Revenue

Other products

17.73 %

of total Revenue

Other products U S

13.12 %

of total Revenue

Other products ROW

4.61 %

of total Revenue

Product sales U S

66.99 %

of total Revenue

Product sales ROW

28.37 %

of total Revenue

Amgen Inc Company Profile

Business Description

Amgen and Kyowa Kirins Rocatinlimab Shows Promise in Phase 3 Study Amid Growth in Supplier Performance

Advancements and Financial Dynamics in Oncological Immunotherapy An Insight into Asher Bio and Amgen Inc.

Fundamental Analysis